Increased serum MFAP4 was observed in hepatocellular carcinoma patients [101,102] and MFAP4 was suggested as a potential biomarker in the serous ovarian cancer due to high expression and association with chemoresistance [103]. The gene discussed is MFAP4; the disease is ovarian serous adenocarcinoma.